Peripartum cardiomyopathy: challenges in diagnosis and management

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 9, 2016, Pages 1035-1041

  Fett, James D ^a,b  

^a Hospital Albert Schweitzer   (Haïti)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

biomarkers; Heart failure; outcomes; PPCM; pregnancy; treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AWARENESS; CARDIOVASCULAR MORTALITY; DISEASE SEVERITY; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; GENETIC PREDISPOSITION; HUMAN; MATERNAL HYPERTENSION; NONHUMAN; PERIPARTUM CARDIOMYOPATHY; PRACTICE GUIDELINE; REVIEW; TREATMENT DURATION; CARDIOMYOPATHIES; COMPLICATION; FEMALE; HYPERTENSION; PATHOPHYSIOLOGY; PERINATAL PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PUERPERAL DISORDERS;

CARDIOMYOPATHIES; DIURETICS; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTENSION; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PUERPERAL DISORDERS;

EID: 84983455362     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1080/14779072.2016.1199273     Document Type: Review

References (36)

1. N.B.Johnson, L.D.Hayes, K.Brown, et al. Centers for Disease Control and Prevention (CDC). CDC national health report:leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005–2013. MMWR Suppl. 2014 Oct 31;63(4):3–27.
2. Z.Arany, U.Elkayam Peripartum cardiomyopathy. Circulation. 2016 Apr 5;133(14):1397–1409. doi:10.1161/CIRCULATIONAHA.115.020491.• Strong on pathophysiology.
3. J.D.Fett Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. Future Cardiol. 2013 Nov;9(6):809–816.
4. J.D.Fett Peripartum cardiomyopathy:a puzzle closer to solution. World J Cardiol. 2014;6(3):81–114. Epub Mar26.• Best comprehensive review of knowledge of PPCM to-date.
5. N.Bello, I.S.H.Rendon, Z.Arany The relationship between preeclampsia and peripartum cardiomyopathy:a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:1715–1723. Epub 2013 Sep4.
6. D.M.McNamara, U.Elkayam, R.Alharethi, et al. Clinical outcomes for peripartum cardiomyopathy in North America:results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905–914.•• Best prospective study PPCM in North America.
7. J.G.Safirstein, A.S.Ro, S.Grandhi, et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012 Jan 12;154(1):27–31. Epub 2010 Sep 20.
8. J.S.Ware, J.Li, E.Mazaika, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. NEJM. 2016 Jan 21;374(3):233–241. doi:10.1056/NEJMoa1505517. Epub 2016 Jan 6.•• Excellent genetic basis analysis of PPCM in recent prospective study.
9. R.Sheppard, E.Hsich, J.Damp, et al. GNB3 C825T polymorphism and myocardial recovery in peripartum cardiomyopathy:results of the multicenter investigations of pregnancy-associated cardiomyopathy study. Circ Heart Fail. 2016 Mar;9(3):e002683.•• Excellent genetic basis analysis of PPCM in recent prospective study.
10. J.D.Fett. Validation of a self-test for early diagnosis of heart failure in peripartum cardiomyopathy. Crit Pathw Cardiol. 2011 Mar;10:44–45.
11. J.Damp, M.M.Givertz, M.Semigran, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy:results of the multicenter IPAC study. JACCHF. 2016 May;4(5):380–388.•• Important new findings on biomarkers in PPCM.
12. T.Umazume, T.Yamada, S.Yamada, et al. Peripartum cardiomyopathy in a woman with preeclampsia with twin pregnancy. BMJ Case Rep. 2014 Nov 20;2014:bcr2014208186. pii:bcr2014208186. doi:10.1136/bcr-2014-208186.
13. I.S.Patten, S.Rana, S.Shahul, et al. Bauersachs cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–338. PMID:22596155. doi:10.1038/nature11040.
14. J.R.Teerlink, G.Cotter, B.A.Davison, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF):a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39.
15. A.Jeyabalan, S.G.Shroff, J.Novak, et al. The vascular actions of relaxin. Adv Exp Med Biol. 2007;612:65–87.
16. S.S.Wilson, S.Ayaz, P.D.Levy. Relaxin:a novel agent for the treatment of acute heart failure. Pharmacotherapy. 2015;35(3):315–327.
17. E.N.Unemori, M.Lewis, J.Constant, et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regener. 2000;8(5):361–370.
18. A.A.Ansari, J.D.Fett, R.E.Carraway, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol. 2002 Dec;23:301–324.
19. R.S.Warraich, K.Sliwa, A.Damasceno, et al. Impact of pregnancy-related heart failure on humoral immunity:clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005;150:263–269.
20. T.Yoshikawa, A.Baba, Y.Nagatomo Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J. 2009;73:602–607. PMID:19246813.
21. J.Liu, Y.Wang, M.Chen The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. PLoS One. 2014;9:e86770. PMID:24466231. doi:10.1371/journal.pone.0086770.
22. R.Jahns, V.Boivin, L.Hein, et al. Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429.• Alerts to importance of autoantibodies in biopathology of PPCM.
23. N.J.Freedmann, R.J.Lefkowitz. Anti–β1-adrenergic receptor antibodies and heart failure:causation, not just correlation. J Clin Invest. 2004;113:1379–1382.
24. D.Hilfiker-Kleiner, K.Kaminski, E.Podewski, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600.
25. K.Sliwa, L.Blauwet, K.Tibazarwa, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy:a proof-of-concept pilot study. Circulation. 2010;121:1465–1473.
26. A.Haghikia, E.Podewski, E.Libhaber, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013;108:366. PMID:23812247. doi:10.1007/s00395-013-0366-9.
27. C.A.Kamiya, M.Kitakaze, H.Ishibashi-Ueda, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011;75(8):1975–1981. Epub 2011 May 27.
28. O.Desplantie, M.Tremblay-Gravel, R.Avram, et al. BRO-HF Initiative Investigators. The medical treatment of new-onset peripartum cardiomyopathy:a systematic review of prospective studies. Can J Cardiol. 2015 Dec;31(12):1421–1426. Epub 2015 May 2.
29. American Heart Association. Heart Failure. In:V.Fuster, editor. The AHA guidelines and scientific statements handbook. Oxford:Wiley-Blackwell; 2009.•• Important to “Follow the Guidellines” in treatment PPCM.
30. C.W.Yancy, M.Jessup, B.Bozkurt, et al. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
31. D.Duncker, A.Haghikia, T.König, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function—value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014;16:1331–1336.
32. J.D.Fett, K.L.Fristoe, S.N.Welsh Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynecol Obstet. 2010;109:34–36.
33. K.L.Baughman. Peripartum cardiomyopathy. Curr Treat Options Cardiovasc Med. 2001 Dec;3(6):469–480.
34. A.M.Amos, W.A.Jaber, S.D.Russell. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152:509–513.
35. J.D.Fett, L.G.Christie, R.D.Carraway, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005 Dec;80:1602–1606.
36. J.D.Fett. Is it safe to discontinue treatment after full recovery from peripartum cardiomyopathy? JACC. 2016;67(13):1297–1287.